Page last updated: 2024-08-24

valsartan and Hypoxia

valsartan has been researched along with Hypoxia in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's1 (16.67)24.3611
2020's3 (50.00)2.80

Authors

AuthorsStudies
Lu, D; Wang, J; Wu, L; Zhang, H1
Dogan, Z; Durmus, S; Ergun, DD; Gelisgen, R; Sahin, H; Senturk, GE; Senyigit, A; Uzun, H1
Hu, J; Liu, S; Liu, W; Lu, S; Wang, Y; Wang, Z; Zeng, X1
Chen, Q; Fang, Y; Li, S; Lv, S; Tian, X; Zhou, H1
Chang, H; Fang, WJ; Liou, JY; Shyu, KG; Wang, BW1
Chen, N; Shi, H; Shi, W; Wang, W; Yu, H; Zhang, B1

Other Studies

6 other study(ies) available for valsartan and Hypoxia

ArticleYear
Sacubitril/valsartan mitigated intermittent hypoxia related intestinal microbiota alteration and aortic injury.
    Sleep & breathing = Schlaf & Atmung, 2023, Volume: 27, Issue:5

    Topics: Animals; Gastrointestinal Microbiome; Hypoxia; Rats; Rats, Sprague-Dawley; Valsartan

2023
Empagliflozin and sacubitril/valsartan reverse methotrexate cardiotoxicity by repressing oxidative stress and hypoxia in heart embryonic H9c2 cardiomyocytes - the role of morphology of mitochondria observed on electron microscopy.
    European review for medical and pharmacological sciences, 2023, Volume: 27, Issue:9

    Topics: Animals; Antioxidants; Cardiotoxicity; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Methotrexate; Microscopy, Electron; Mitochondria; Myocytes, Cardiac; Oxidants; Oxidative Stress; Rats; Valsartan

2023
Sacubitril/valsartan treatment relieved the progression of established pulmonary hypertension in rat model and its mechanism.
    Life sciences, 2021, Feb-01, Volume: 266

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Body Weight; Disease Models, Animal; Disease Progression; Drug Combinations; Hypertension, Pulmonary; Hypoxia; Male; Monocrotaline; Rats; Rats, Sprague-Dawley; Tetrazoles; Valsartan

2021
Opiorphin increases blood pressure of conscious rats through renin-angiotensin system (RAS).
    Peptides, 2014, Volume: 55

    Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Captopril; Hypotension; Hypoxia; Male; Oligopeptides; Rats, Wistar; Renin-Angiotensin System; Salivary Proteins and Peptides; Tetrazoles; Valine; Valsartan

2014
Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart.
    Journal of biomedical science, 2005, Volume: 12, Issue:2

    Topics: Acetylcysteine; Animals; Antihypertensive Agents; Aorta; Arteries; Blotting, Western; Body Weight; Carbazoles; Carvedilol; Down-Regulation; Doxazosin; Echocardiography; Hemodynamics; Hypertrophy; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Myocardium; Nerve Growth Factor; Organ Size; Pressure; Propanolamines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Transcription Factors; Valine; Valsartan; Vascular Endothelial Growth Factor A; Vasodilator Agents

2005
Peritubular capillary loss is ameliorated by ramipril or valsartan treatment.
    Microcirculation (New York, N.Y. : 1994), 2008, Volume: 15, Issue:4

    Topics: Animals; Antihypertensive Agents; Capillaries; Gene Expression Regulation; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Tubules; Male; Microcirculation; Ramipril; Rats; Rats, Sprague-Dawley; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan

2008